Free Daily Podcast Summary
Pharmaceutical Executive: Daily Summaries Delivered
by Pharmaceutical Executive Podcast
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Yesterday3 min
Pharmaceutical Executive Daily: FDA Votes 10 to 3 in Favor of Replimune's Rp1 Efficacy Data
In today's Pharmaceutical Executive Daily, FDA's advisory committee votes in favor of Replimune's RP1 efficacy data in advanced melanoma, three clinical-stage biopharmaceutical companies file for IPOs spanning cardiovascular, immune, and metabolic disease, and a new analysis examines why two-thirds of pharmaceutical product launches fail to meet expectations.
- 2 days ago3 min
Pharmaceutical Executive Daily: Inizio Engage launches Connected Insights
In today's Pharmaceutical Executive Daily, Johnson & Johnson, Processa Pharmaceuticals, and Relation strike new deals spanning cell therapy, BTK inhibition, and AI-driven target discovery, Inizio Engage launches Connected Insights to turn medical information interactions into strategic intelligence, and a commentary argues pharma companies need to manage direct-to-patient sales as a core commercial channel rather than a side program.
- 3 days ago3 min
Pharmaceutical Executive Daily: FDA Approves Viatris's Gwyn Lo
In today's Pharmaceutical Executive Daily, a commentary examines why fragmented software tooling causes scientific judgment to get lost across the biologics R&D pipeline, Replimune shares crash nearly 32 percent after FDA reviewers raise concerns about its melanoma therapy, and FDA approves Viatris's Gwyn Lo as a new once-weekly contraceptive patch.
- 3 days ago10 min
The Ron Lanton Report: The Human Bottleneck
In this episode, Ron Lanton argues that healthcare's next constraint isn't capital or technology but rather people.
- 3 days ago10 min
Pharmaceutical Executive Daily: BioMarin and n-Lorem Foundation Enter Collaboration
In today's Pharmaceutical Executive Daily, BioMarin and n-Lorem Foundation partner on the first disease-targeted therapy for the recently identified ReNU syndrome, a trio of biotech financings advance rare disease, sleep apnea, and oncology pipelines, and a Wharton professor offers career advice for MBA graduates navigating an AI-reshaped job market.
- 4 days ago3 min
Pharmaceutical Executive Daily: FDA Approves Simtriyo
In today's Pharmaceutical Executive Daily, FDA approves Otsuka's Simtriyo as the first NDSRI treatment for ADHD, argenx agrees to acquire Forte Biosciences for approximately $2.2 billion, and an AbbVie neuroscience researcher discusses the shift from symptom management to disease modification in Parkinson's research.
- 1 weeks ago3 min
Pharmaceutical Executive Daily: FDA Votes to Reduce Restrictions on Four Peptides
In today's Pharmaceutical Executive Daily, an FDA advisory panel narrowly votes to recommend easing restrictions on four unapproved peptides, a supply chain expert discusses how China's export controls are exposing vulnerabilities in the U.S. pharmaceutical supply chain, and a pharmacy benefits executive lays out a business case for more targeted employer-based GLP-1 coverage.
- 1 weeks ago3 min
Pharmaceutical Executive Daily: Eli Lilly Reports Positive Results from Two Phase III Trials
In today's Pharmaceutical Executive Daily, Eli Lilly's Retatrutide delivers up to 22.6% weight loss in two new Phase III trials, a clinical trial expert discusses why the U.S. is losing trial volume to Australia and China, and a pharmacy benefits executive weighs in on why short-term cost thinking is complicating GLP-1 coverage decisions.
About Pharmaceutical Executive
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Pharmaceutical Executive in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Pharmaceutical Executive daily summary?
It's a free AI-powered email that summarizes new episodes of Pharmaceutical Executive as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Pharmaceutical Executive podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Pharmaceutical Executive product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Pharmaceutical Executive Podcast.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does Pharmaceutical Executive release new episodes?
Pharmaceutical Executive publishes daily. Our AI generates a summary within hours of each new episode.
What topics does Pharmaceutical Executive cover?
Pharmaceutical Executive covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Pharmaceutical Executive summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.